Elixirgen Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Rollover Study From EXG-US-01
Phase 1
- Conditions
- Telomere Biology Disorders With Bone Marrow Failure
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Elixirgen Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05868499
- Locations
- 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Elixirgen Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04211714
- Locations
- 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
News
No news found